Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Head & Neck 2Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 4399Urinary Bladder Neoplasms 1078Carcinoma, Renal Cell 1041Kidney Neoplasms 567Breast Neoplasms 453Neoplasms 403Carcinoma, Transitional Cell 297Neoplasm Metastasis 250Lung Neoplasms 242Testicular Neoplasms 202Melanoma 194Colorectal Neoplasms 193Ovarian Neoplasms 163Carcinoma, Non-Small-Cell Lung 150Non-Muscle Invasive Bladder Neoplasms 135Sarcoma 134Pancreatic Neoplasms 124Colonic Neoplasms 121Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Wilms Tumor 108Recurrence 106Motor Activity 100Stomach Neoplasms 89Urologic Neoplasms 88Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 79Adenocarcinoma 78

Interventions

ascrinvacumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Camurati-Engelmann Syndrome × Genitourinary × Clear all
NCT01620970 2021-05-14

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed
14 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡